Synlogic, Inc.: Revision history

20 August 2022

• curprev 19:2419:24, 20 August 2022 95.149.241.133 talk 1,016 bytes +11 No edit summary undo

14 August 2022

• curprev 05:4805:48, 14 August 2022 109.180.50.163 talk 1,005 bytes +15 No edit summary undo

31 July 2022

• curprev 08:5808:58, 31 July 2022 >Chris 990 bytes +990 Created page with "Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat..."